Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aegerion Juxtapid Launch Targets Population Far Broader Than FDA Projection

Executive Summary

Aegerion says feedback from key opinion leaders and market research indicate the market for its homozygous hypercholesterolemia drug may be as many as 3,000 patients; FDA estimates put the number at 315.

You may also be interested in...

Repurposing Leptin (Part 2): It Really Is A One-In-A-Million Drug

Two decades after the “obesity gene” was the hottest story in biotech, a product from that research is finally going to reach the market. But it is for a disease that occurs in about .0001% of the US population.

EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).

Disease Severity Underlies Advisory Committee Support For Kynamro

FDA’s Metabolic and Endocrinologic Advisory Committee votes 9 to 6 in favor of Genzyme’s mipomersen for homozygous familial hypercholesterolemia Oct. 18.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts